Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery

Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news

Spotlight On: What to Watch at AHA 2025 – Key Science and Trends

AHA 2025; late-breaking science; clinical trials; cardiology; gene-editing therapies; polypill; lipid management; valve and coronary trials; cardiometabolic intervention; hypertension; CPR guidelines

Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat

ObesityWeek 2025; non-incretin therapies; naltrexone-bupropion; CONTRAVE; weight management; craving control; behavioral adherence; pharmaceutical innovation; cardiometabolic health

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience

Chronic care startup Omada Health files to go public

Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health